Mendus

Mendus

Sweden - Stockholm
Biotechnology

Focus: Cell Therapy for Immuno-Oncology

Mendus is a life sciences company focused on Cell Therapy for Immuno-Oncology.

OncologyGene TherapyCell Therapy
Funding Stage
PUBLIC
Open Jobs
0

Pipeline & Clinical Trials

Clinical Trials (1)
NCT02686944A Study to Evaluate the Safety of Intuvax Administered Intra-tumorally in Patients With Gastrointestinal Stromal Tumors
Phase 1
Clinical Trials (1)
NCT03735290A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer
Phase 1
Phase 1
Clinical Trials (1)
NCT01974661Phase I Safety Study of Dendritic Cell Vaccine to Treat Patients With Hepatocellular Carcinoma
Phase 1
Clinical Trials (1)
NCT01525017A Clinical Study to Evaluate Safety and Immunologic Response of COMBIG-DC, in Patients With Metastatic Kidney Cancer
Phase 1
Phase 1
Clinical Trials (1)
NCT04739527Phase 1 Study to Evaluate the Safety, Feasibility and Immunogenicity of an Allogeneic, Cell-based Vaccine (DCP-001) in High Grade Serous Ovarian Cancer Patients After Primary Treatment
Phase 1
Clinical Trials (1)
NCT01373515Leukemic Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia
Phase 1/2
Clinical Trials (1)
NCT02432846Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC)
Phase 2
Clinical Trials (1)
NCT03697707Efficacy and Safety of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia
Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Founded: 2022
Portfolio: 8 clinical trials